1-3 of 3
David Rice, RN
Close
Sort by
Journal Articles

Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.

Bradford S. Hoppe, MD, Joachim Yahalom, MD, Tarun Kewalramani, MD, Paul A. Hamlin, MD, David Rice, RN, Daniel Filippa, MD, Jocelyn Maragulia, Alandra Weaver, Craig H. Moskowitz, MD
Journal: Blood
Blood (2007) 110 (11): 1893.
https://doi.org/10.1182/blood.V110.11.1893.1893
Published: 2007
Journal Articles

The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).

Daniel Persky, MD, Carol S. Portlock, MD, Simone Lessac-Chenen, BA, Alexia Iasonos, Ph.D, Andrew D. Zelenetz, MD, Ph.D, Tarun Kewalramani, MD, David Rice, RN, NP-C, Joachim Yahalom, MD, Stephen D. Nimer, MD, Craig H. Moskowitz, MD.
Journal: Blood
Blood (2005) 106 (11): 2072.
https://doi.org/10.1182/blood.V106.11.2072.2072
Published: 2005
Journal Articles

High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma.

Daniel Persky, MD, Julie Teruya-Feldstein, MD, Tarun Kewalramani, MD, Pauline D. Bonner, BA, Alexia Iasonos, Ph.D, David Rice, RN, NP-C, Joachim Yahalom, MD, Stephen D. Nimer, MD, Andrew D. Zelenetz, MD, Ph.D, Craig H. Moskowitz, MD
Journal: Blood
Blood (2005) 106 (11): 2073.
https://doi.org/10.1182/blood.V106.11.2073.2073
Published: 2005